Akorn, Inc., a prominent player in the pharmaceutical industry, is headquartered in the United States and operates extensively across North America. Founded in 1971, the company has established itself as a leader in the development, manufacturing, and marketing of specialty pharmaceuticals, particularly in the areas of ophthalmology, anaesthesia, and injectables. With a diverse portfolio of products, Akorn is recognised for its commitment to quality and innovation, offering unique formulations that cater to specific patient needs. The company has achieved significant milestones, including the expansion of its manufacturing capabilities and a robust pipeline of generic and branded medications. Akorn's strategic focus on niche markets has solidified its position as a trusted provider in the competitive pharmaceutical landscape.
How does Akorn's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Akorn's score of 29 is lower than 50% of the industry. This can give you a sense of how well the company is doing compared to its peers.
As of the latest available data, Akorn has not reported any specific carbon emissions figures. However, the company has established significant climate commitments aimed at achieving net-zero carbon emissions. Akorn's initiatives include a near-term target for new buildings to be net-zero carbon emitters by 2030 and existing buildings by 2050, focusing on Scope 1 emissions. This commitment reflects a proactive approach to sustainability in the property sector, particularly in markets such as the United Kingdom. While no specific reduction percentages or absolute emissions data are available, Akorn's long-term vision aligns with global trends towards stringent climate policies and sustainable building practices. The absence of reported emissions data suggests that Akorn is in the early stages of its climate strategy, with a clear focus on future compliance and environmental responsibility.
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Akorn has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
